IENT ENROLLMENT FORM

Submit a completed form by fax 1-833-469-8333 or email TEPEZZAHBYS@horizontherapeutics.com





and/or assistance obtaining patient signature, call Horizon By Your Side at 1-833 **PATIENT INFORMATION** O Male First name* Last name* Date of birth*: __/__/___/ (MM/DD/YYYY) Primary language O Home Consent to: Primary Phone Number* Send text message? O Yes O No Leave voice message? O Yes O No Email address Address* Citv* State* Zip code* Alternate contact name Alternate contact telephone **DIAGNOSIS** (Required for benefits investigation.) O Primary diagnosis code* E05.00 — Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm (hyperthyroidism) Date of initial Additional disease Thyroid Eye Disease manifestation codes: (TED) diagnosis: Patient's Clinical Activity Score (CAS) [0-10 Range]: **INSURANCE INFORMATION** Complete the following OR attach front-back copies of insurance card(s). Primary Insurance* Secondary Insurance Policy #* Policy # Policyholder's first and last name* Policyholder's first and last name Insurance company telephone* Insurance company telephone Group #* Group # Policyholder's DOB*: DOB: IPA/Medical group Name IPA/Medical group Phone Number O Patient is uninsured to my knowledge. State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber. **PATIENT AUTHORIZATION** D-41--4 -1----

	Please read page 2	Date (MM/DD/				
	Printed full name	-				
Please see Important Safety Information on next page and <u>Full Prescribing Information</u> at TEPEZZAhcp.com.						
Page 1	of 2					

Initiate the patient enrollment proce and/or assistance obtaining patient s						P-TEP-US-00323-5	
PATIENT INFORMATION			PRESCRIBER IN	FORMATION			
		OMale					
First name* Last	name*	Sex: O Female	First name*		Last name*		
Date of birth*://			Address*				
(MM/DD/YYYY)	Primary lar	nguage	City*		State*	Zip code*	
Primary Phone Number* O Cel	Consent to						
		message? O Yes O No e message? O Yes O No	NPI #*	Tax ID #*		State license #*	
Email address	_ Leave voice	inessage: O res O res	Clinic/hospital affiliati	on			
Address*			Office contact name*		Office contact	telephone*	
City*	State*	Zip code*	Office Contact Email	Address*	Fax* Preferr	ed O Telephone	
Alternate contact name	Alternate co	ntact telephone	Specialty:			unication: OEmail	
DIAGNOSIS (Required for benefit	s investigation.)		REFERRING PHY	SICIAN (Completed physician	i.They will be par	sent to you by another t of the patients care team.)	
(,	, <u> </u>		First and Last Name			ecialty	
Primary diagnosis code* E05.00 — thyrotoxic crisis or storm (hyperthy	•	with diffuse goiter without	First and Last Name Address			естату	
Additional disease	Date of initial	innan					
manifestation codes:	Thyroid Eye D (TED) diagnos	sis:/	City State		Zip code Telephone		
		(MM/YYYY)	PREFERRED IN	FUSION FACI	LITY (If none	e, Horizon By Your Side ovide options.)	
Patient's Clinical Activity Score (CAS)	[0-10 Range]:		Facility name	Fax Number			
INCURANCE INFORMATIO	N.					(Trainiber	
INSURANCE INFORMATIO		as of income as a soul(a)	Address				
Complete the following OR attach	ггопт-раск сорі	es or insurance card(s).	City	State Zip	code	Telephone	
Primary Insurance*	Secondary Ir	nsurance	Facility NPI #		Tax ID #		
	_		-			anefit or home infusion)	
Policy #*	Policy #		PRESCRIPTION (Required for specialty pharmacy benefit or home infusion.) Medication: TEPEZZA* (teprotumumab-trbw) for injection, for intravenous use //500-mg vial				
Policyholder's first and last name* Policy		's first and last name	Directions: 1 peripheral IV infusion every 3 weeks for a total of 8 infusion Administer the first 2 infusions over 90 minutes. Subsequent infusions make reduced to 60 minutes, if tolerated. Please see Dosing and Administra			total of 8 infusions.	
Insurance company telephone*	Insurance co	mpany telephone	section of Prescribing Information for additional instruct Dose*: Infusion 1: mg (10mg/kg) Infusions 2-8:		ction.		
Group #*	Group #					ply; 1 prescription; 6 refills	
Policyholder's / /	Policyholder's	//	Weight*:	O lbs O kg	TEPEZZ	Adosing.com	
DOB*: (MM/DD/YYYY)	DOB:	(MM/DD/YYYY)	Allergies*:	or ONo ki	No known drug allergies (NKDA)		
IPA/Medical group Name IPA/Medical group Phone Number			O Patient is Medically Urgent. I attest the patient is both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2)				
O Patient is uninsured to my knowled	dge.		requires accelerated treatment with TEPEZZA. Nursing orders for home infusion: Provide skilled nursing visit to administer				
State requirements: The prescriber is prescription requirements such as e-	prescribing, stat	e-specific prescription	medication, provide Saline flushes and o			quired for home infusion) norized as needed.	
form, fax language, etc. Noncompliai could result in outreach to the presci		oecific requirements	Fluids for reconstitution Sterile Water for Injection Sodium Chloride Injection doses ≥ 1800 mg, use a	on, USP. Administer on, USP. For doses	r via an infusior	n bag containing 0.9%	
PATIENT AUTHORIZATION					(Required—plea	se see certification	
X		, ,	PRESCRIBER CE	RTIFICATION	language on the	se see certification next page.)	
Patient signature		Date (MM/DD/YYYY)	×			/ /	
Please read page 2			Prescriber signa	ature/Dispense as	written*	Date (MM/DD/YYYY)	
Printed full name		-	Substitutions all	owed		tten or e-signature only;	
Please see Important Safety Inf	ormation on r	next page and	O I certify that the				

treatment of documented Thyroid Eye Disease (TED)*

The above signature grants permission to share records with the co-management team and infusion facility.

Prescriber Certification

Please read and provide signature in Prescriber Certification section on page 1

I certify that the above therapy is medically necessary, that the information provided is accurate to the best of my knowledge and that my patient is being administered TEPEZZA (teprotumumab-trbw), for intravenous infusion in accordance with the labeled use of the product. I understand that Horizon Therapeutics USA, Inc. and its affiliates and their respective employees or agents (collectively, "Horizon") will use this information to administer the Horizon By Your Side program (the "Program"), which provides a wide array of patient-focused services, including providing logistical and non-medical treatment support for TEPEZZA, as prescribed, and educating about the insurance process. I authorize these parties to act on my behalf for the limited purposes of transmitting this prescription by facsimile to the appropriate pharmacy designated by the patient utilizing their benefit plan. By my signature, I also certify that (I) my patient or his/her personal representative has provided a signed HIPAA authorization that allows me to share protected health information with Horizon for purposes of the Program and (2) I have obtained the patient's authorization to release such information as may be required for AllCare Plus Pharmacy (or another party acting on behalf of Horizon) to assess insurance coverage for TEPEZZA and assistance in initiating or continuing TEPEZZA as prescribed. I further understand and agree that (a) any medication or service provided through the Program as a result of this form is for the named patient only and is not being made in exchange for any express or implied agreement or understanding that I would recommend, prescribe, or use TEPEZZA or any other Horizon product or service, for any other person; (b) my decision to prescribe TEPEZZA was based solely on my professional determination of medical necessity; and (c) I will not seek reimbursement for any medication or service provided by or through the Program from any government program or third-party insurer. I understand that Horizon may modif

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

By filling out and signing this form, the enrollment process in Horizon By Your Side has initiated; however, your patient must sign a Patient Authorization to complete enrollment in Horizon By Your Side. Please note that your patient will not benefit from the services and support offered by the Program unless your patient signs a Patient Authorization, consenting to receiving such services. If your patient does not sign the Patient Authorization contained within this form, Horizon will contact the patient to determine whether the patient is interested in signing a separate Patient Authorization.

Patient Consent for Patient Information, Enrolling in Services, and Accessing Financial Support (referred to as "Patient Authorization") Please read and provide signature in Patient Authorization section on page 1

I hereby authorize my healthcare providers, my health insurance carriers, and my pharmacies to use and disclose my individually identifiable health information, including my medical records, insurance coverage information, and my name, address, and telephone number to Horizon Therapeutics USA, Inc. and its affiliates and their respective agents and representatives (collectively, "Horizon"), including third parties authorized by Horizon to administer drug support and to dispense drugs (collectively, "Horizon By Your Side") for the following purposes: (1) to establish eligibility for benefits; (2) to communicate with my healthcare providers and me about my treatment or condition and related products; (3) to facilitate the provision of products, supplies, or services by a third party including, but not limited to, specialty pharmacies; (4) to register me in any applicable product registration program required for my treatment; (5) to enroll me in eligible patient support programs offered by Horizon By Your Side and/or Horizon, including nursing or patient access support services (government-reimbursed programs may not be eligible for all support services offered; please contact Horizon By Your Side for determination); and (6) to send me marketing information or offer me products and services related to my treatment or condition (or other products or services in which I might be interested) and to contact me occasionally to obtain my feedback (for market research purposes only) about my treatment, my condition, or my experience with Horizon and/or Horizon By Your Side otherwise as required or permitted by law. Further, I appoint the Program, on my behalf, to proceed with Program services and to convey this prescription to the dispensing pharmacy, to the extent permitted under state law. I understand the pharmacies may receive a fee from Horizon in exchange for (1) providing me with certain materials and information described above, and (2) using or disclosing certain health information pursuant to this Authorizatio

I understand that Horizon, as well as my healthcare providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment, or other care, to sign this Authorization. I understand that I am entitled to a copy of this Authorization.

I understand that information disclosed pursuant to this Authorization in some cases may be redisclosed by the recipient and no longer protected by HIPAA or other privacy laws. But Horizon has agreed to use and disclose my information only for purposes of operating the Program. I understand that I may cancel this Authorization at any time by mailing a signed letter requesting such cancellation to Horizon By Your Side, 1 Horizon Way, Deerfield, IL 60015, but that this cancellation will not apply to any information used or disclosed by my healthcare providers and/or health insurance carriers based on this Authorization before they are notified that I have cancelled it. Unless required by state law, this Authorization is valid for whichever is greater: (a) the duration remaining on this treatment or (b) 10 years from the date signed on page 1. A photocopy of this Authorization will be treated in the same manner as the original.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.



TEPEZZA and the HORIZON logo are trademarks owned by or licensed to Horizon. © 2023 Horizon Therapeutics plc P-TEP-US-00323-5 09/23

